What does Edgewise Therapeutics, Inc. do?
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies…
What is Edgewise Therapeutics, Inc.'s P/E and P/B ratio?
Edgewise Therapeutics, Inc. has a P/E ratio of -21.5 and a P/B ratio of 9.69.
What is Edgewise Therapeutics, Inc.'s debt-to-equity ratio?
Edgewise Therapeutics, Inc. has a debt-to-equity ratio of 0.01.
How much does Edgewise Therapeutics, Inc. owe compared with what it owns?
Edgewise Therapeutics, Inc. owes $0.07 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Edgewise Therapeutics, Inc.'s Positivity rank?
Edgewise Therapeutics, Inc. is ranked #5,822 of 6,774 companies globally and #3,239 of 4,000 in United States on PositoAI, with a Positivity Score of 15,022.
Does Edgewise Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Edgewise Therapeutics, Inc..
Where can I read the latest news about Edgewise Therapeutics, Inc.?
Recent headlines about Edgewise Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Edgewise Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Edgewise Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.